stockrowMedpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) Revenue
Medpace Holdings, Inc.'s revenue for fiscal 2025 was $2.5B, up 20.0% from $2.1B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.8B. Over the past ten years it has ranged from $359.1M (fiscal 2015) to $2.5B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. Medpace Holdings, Inc. ranks 15th of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.5B | 19.97% |
| FY2024 | $2.1B | 11.84% |
| FY2023 | $1.9B | 29.17% |
| FY2022 | $1.5B | 27.80% |
| FY2021 | $1.1B | 23.38% |
| FY2020 | $925.9M | 7.54% |
| FY2019 | $861.0M | 22.19% |
| FY2018 | $704.6M | 61.55% |
| FY2017 | $436.2M | 3.46% |
| FY2016 | $421.6M | 17.41% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $716.0M | 1.23% |
| Jun 2026 | $707.3M | 0.10% |
| Mar 2026 | $706.6M | (0.26%) |
| Dec 2025 | $708.4M | 7.36% |
| 40 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| LH Labcorp Holdings Inc. compare | $14.6B |
| DGX Quest Diagnostics Incorporated compare | $11.8B |
| ICLR ICON PLC compare | $8.2B |
| ILMN Illumina, Inc. compare | $4.5B |
| CRL Charles River Laboratories International, Inc. compare | $4.0B |
| RVTY Revvity Inc. compare | $2.9B |
| MEDP Medpace Holdings, Inc. | $2.8B |
| QGEN QIAGEN N.V. compare | $2.1B |
| GH Guardant Health, Inc. compare | $1.3B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on MEDP
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement